CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.11 Consensus Price Target from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has received an average rating of “Hold” from the twenty-one brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $73.11.

Several research firms recently issued reports on CRSP. Royal Bank of Canada dropped their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Truist Financial lifted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research note on Wednesday, February 12th. Finally, Morgan Stanley lifted their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th.

CRISPR Therapeutics Trading Up 0.3 %

NASDAQ:CRSP opened at $42.12 on Thursday. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of -9.64 and a beta of 1.77. The firm’s fifty day simple moving average is $43.06 and its 200 day simple moving average is $45.56. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 in the last quarter. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRSP. Axxcess Wealth Management LLC boosted its stake in CRISPR Therapeutics by 3.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 10,271 shares of the company’s stock valued at $483,000 after purchasing an additional 330 shares during the period. State of New Jersey Common Pension Fund D lifted its stake in shares of CRISPR Therapeutics by 16.8% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 40,341 shares of the company’s stock worth $1,895,000 after acquiring an additional 5,803 shares during the period. Aigen Investment Management LP acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $298,000. Oppenheimer & Co. Inc. lifted its stake in shares of CRISPR Therapeutics by 7.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 34,128 shares of the company’s stock worth $1,603,000 after acquiring an additional 2,478 shares during the period. Finally, KBC Group NV lifted its stake in shares of CRISPR Therapeutics by 43.9% in the 3rd quarter. KBC Group NV now owns 2,818 shares of the company’s stock worth $132,000 after acquiring an additional 860 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.